Non-alcoholic fatty liver disease: Current concepts and management strategies

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 6, Issue 1, 2006, Pages 19-25

  Day, Chris P ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; BETAINE; CYTOKINE; CYTOKINE ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TUMOR NECROSIS FACTOR ANTIBODY; URSODEOXYCHOLIC ACID;

CLINICAL FEATURE; EPIDEMIC; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; REVIEW;

EID: 33644504852     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.6-1-19     Document Type: Review

References (60)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C et al. Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
3. Bellentani S, Saccoccio G, Masutti F, Croce LS et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-7.
4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Review. Hepatology 2003;37:1202-19.
5. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Review. Gastroenterobgy 2005;129:375-8.
6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
7. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6.
8. Ratziu V, Bonyhay L, Di Martino V, Charlotte F et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93.
9. Adams LA, Lymp JF, St Sauver J, Sanderson SO et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
10. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-5.
11. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
12. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
13. Brunt EM. Nonalcoholic steatohepatitis. Review. Semin Liver Dis 2004;24:3-20.
14. Kleiner DE, Brunt EM, Van Natta M, Behling C et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
15. Ratziu V, Charlotte F, Heurtier A, Gombert S et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
16. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-9.
17. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
18. Saadeh S, Younossi ZM, Remer EM, Gramlich T et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
19. Castera L, Vergniol J, Foucher J, Le Bail B et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
20. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
21. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005;43:78-84.
22. Rosenberg WM, Voelker M, Thiel R, Becka M et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
23. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:663-78.
24. Day CP. From fat to inflammation. Gastroenterology (in press).
25. Weisberg SP, McCann D, Desai M, Rosenbaum M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
26. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-94.
27. Cai D, Yuan M, Frantz D, Melendez PA et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005;11:183-90.
28. Hui JM, Hodge A, Farrell GC, Kench JG et al. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2004;40:46-54.
29. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002;35:762-71.
30. Bataller R, Schwabe RF, Choi YH, Yang L et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-94.
31. Oben JA, Roskams T, Yang S, Lin H et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun 2003;308:284-92.
32. Paradis V, Perlemuter G, Bonvoust F, Dargere D et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34(4 Pt 1):738-44.
33. Kamada Y, Tamura S, Kiso S, Matsumoto H et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796-807.
34. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995;310:555-9.
35. Marchesini G, Bugianesi E, Forlani G, Cerrelli F et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
36. International Diabetes Federation. The IDF consensus worldwide definitions of the metabolic syndrome. Available at: http:// www.idf.org (accessed 6 November 2005)
37. Isomaa B, Almgren P, Tuomi T, Forsen B et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
38. Musso G, Gambino R, De Michieli F, Cassader M et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-16.
39. Ueno T, Sugawara H, Sujaku K, Hashimoto Octal. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7.
40. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-8.
41. Kral JG, Thung SN, Biron S, Mould FS et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58.
42. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54.
43. Bugianesi E, McCullough AJ, Marchesisini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
44. Bugianesi E, Gentilcore E, Manini R, Natale S et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
45. Galli A, Crabb DW, Ceni E, Salzano R et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-40.
46. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
47. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis alter 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
48. Laurin J, Lindor KD, Crippin JS, Gossard A et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-7.
49. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92.
50. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-50.
51. Yokohama S, Yoneda M, Haneda M, Okamoto S et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5.
52. Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003;38:414-8.
53. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-7.
54. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-8.
55. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90.
56. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-8.
57. Yuan M, Konstantopoulos N, Lee J, Hansen L et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science 2001;293:1673-7.
58. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
59. Contos MJ, Cales W, Sterling RK, Luketic VA et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-73.
60. Ong J, Younossi ZM, Reddy V, Price LL et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.